Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 3-part Open-label Study Assessing Safety, Tolerability, Pharmacokinetic and -Dynamic Profiles, and Efficacy of Tofacitinib in Young Adults From Age 18 to 45 With Moderate to Severe Skin Involvement Due to Lupus

Trial Profile

A 3-part Open-label Study Assessing Safety, Tolerability, Pharmacokinetic and -Dynamic Profiles, and Efficacy of Tofacitinib in Young Adults From Age 18 to 45 With Moderate to Severe Skin Involvement Due to Lupus

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Feb 2019

At a glance

  • Drugs Tofacitinib (Primary)
  • Indications Cutaneous lupus erythematosus; Systemic lupus erythematosus
  • Focus Pharmacokinetics
  • Most Recent Events

    • 31 Jan 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Jan 2020.
    • 11 Jul 2018 Planned primary completion date changed from 1 Aug 2018 to 1 Dec 2018.
    • 22 Sep 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top